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Aims/Introduction: Incretin therapy is a common treatment for type 2 diabetes mellitus. 
We have previously reported an anti-prostate cancer effect of glucagon-like peptide-1 
receptor (GLP-1R) agonist exendin-4. The attenuation of cell proliferation in prostate 
cancer cell line was dependent on GLP-1R expression. Here, we examined the 
relationship between human prostate cancer severity and the effect of forced expression 
of GLP-1R using a lentiviral vector. 
Materials and Methods: Prostate cancer tissues were extracted by prostatectomy and 
biopsy. GLP-1R was overexpressed in ALVA-41 cells using a lentiviral vector (ALVA-
41-GLP-1R cells). GLP-1R expression was detected by immunohistochemistry and 
quantitative PCR. Cell proliferation was examined by growth curves and BrdU 
incorporation assays. Cell cycle distribution and regulators were examined by flow 
cytometry and western blotting. In vivo experiments were performed using a xenografted 
model.  
Results: GLP-1R expression levels were significantly inversely associated with the 
Gleason score of human prostate cancer tissues. Abundant GLP-1R expression and 
functions were confirmed in ALVA-41-GLP-1R cells. Exendin-4 significantly decreased 
ALVA-41-GLP-1R cell proliferation in a dose-dependent manner. DNA synthesis and 
G1-to-S phase transition were inhibited in ALVA-41-GLP-1R cells. SKP2 expression 
was decreased and p27Kip1 protein was subsequently increased in ALVA-41-GLP-1R 
cells treated with exendin-4. In vivo experiments performed by implanting ALVA-41-
GLP-1R cells demonstrated that exendin-4 decreased prostate cancer growth by 
activation of GLP-1R overexpressed in ALVA41-GLP-1R cells.  
Conclusions: Forced expression of GLP-1R attenuates prostate cancer cell proliferation 
by inhibiting cell cycle progression in vitro and in vivo. Therefore, GLP-1R activation 
may be a potential therapy for prostate cancer. 
 










Anti-diabetic agents mimicking incretin action, such as dipeptidyl peptidase-4 
(DPP-4) inhibitors and glucagon-like peptide-1 receptor (GLP-1R) agonists, have 
emerged as one of pivotal treatments for patients with type 2 diabetes mellitus (T2DM). 
Incretin action is recently taking the limelight because of their direct organ-protective 
effects that are provided independent on the beneficial effects associated with glucose 
lowering effect 1. Patients with T2DM have a higher risk of cardiovascular diseases2 and 
highly potential for restenosis after coronary angioplasty3 than individuals without T2DM. 
Consequently, the potential of anti-diabetic treatments using incretin action to advantage 
not only glycaemic control but also the protection of cardiovascular system has been 
elucidated. Previously, we have investigated such protective effects on vascular systems 
including attenuation of atheroma formation in atherogenic mice4 and the reduction of 
vascular constriction after injury5, 6 induced by a GLP-1R agonist exendin-4 (Ex-4). Thus, 
incretin therapy might be able to ameliorate quality of life and reduce mortality rates 
among patients with T2DM according to its vascular protection. 
 However, cancer, malignant neoplasms, is currently focused on as a central cause 
of death in patients with T2DM7. In particular, cancer has become the leading causal 
disease of death in Japanese patients with T2DM. The Japan Diabetes Society (JDS) and 
Japan Cancer Association (JCA) have therefore issued a warning about increasing cancer 
risk in patients with DM8. The current Japan Diabetes Optimal Integrated Treatment study 
for 3 major risk factors of cardiovascular diseases (J-DOIT3) study revealed that 
multifactorial intensive intervention reduces cardiovascular events in Japanese patients 
with T2DM9. However, J-DOIT3 did not reduce the risk of all mortalities and cancer 
death by multifactorial intervention9. This result suggests that to establishment a new 
treatment strategy to reduce cancer and associated deaths for T2DM is required. 
 Previously, we have observed GLP-1R expression in post-operative prostate 
cancer tissue in non-diabetic subjects and demonstrated the attenuation of prostate cancer 
growth by Ex-4 via inhibiting ERK activation both in vitro and in vivo10. In addition, 
further reductions in tumor growth and prostate cancer cell proliferation were observed 
by combination treatment with Ex-4 and metformin11, without a relationship to glucose 
reduction. Following our experimental demonstrations, the LEADER trial, Liraglutide 
Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results, revealed 
that the GLP-1R agonist decreased the prostate cancer prevalence significantly in patients 
with T2DM, suggesting that GLP-1R agonists attenuate prostate cancer growth in not 
only experimental animal models, but also patients with T2DM12. In our previous report, 
the anti-prostate cancer effect induced by Ex-4 was dependent on GLP-1R expression in 
cancer cells, and Ex-4 did not attenuate the proliferation of human prostate cancer cell 
line ALVA-41 that does not express endogenous GLP-1R10. To elucidate the precise anti-
prostate cancer effect of GLP-1R activation, we examined the relationship between 
human prostate cancer severity and GLP-1R expression, and the effect of forced 
expression of GLP-1R using a lentiviral vector in ALVA-41 cells in vitro and in vivo. 
 
MATERIALS AND METHODS 
Human tissues 
Human prostate cancer tissues were obtained from 30 non-diabetic subjects with prostate 
cancer aged from 20 to 85 years after radical prostatectomy or transrectal biopsy in 
Fukuoka University Hospital. The samples were embedded in paraffin, fixed in formalin, 
and cut into 3 µm-thick sections for immunofluorescence staining. Sections were 
prepared from 30 independent prostate cancers of 30 independent patients. The tissue 
samples were categorized into three malignancy grades by the Gleason grading system13. 
The Ethical Committee of Fukuoka University Hospital approved the protocol of this 
study (15-2-03) with opt-out consent provided by the hospital website 
(http://www.hop.fukuoka-u.ac.jp/rinshou/download/PDF(15-2-03).pdf). The present 
study was carried out in accordance with the principles of the Declaration of Helsinki. 
Immunohistochemistry 
Paraffin-embedded tissue sections were stained with an anti-GLP-1R monoclonal 
antibody (Mab 3F52)14 obtained from Novo Nordisk and an anti-P504S antibody 
(AN449-5ME; Biogenex, CA). Sections for GLP-1R staining were subsequently 
incubated with Alexa Fluor 488 goat anti-mouse IgG (A-11017, Life Technologies, 
CA), and sections for P504S staining were incubated with Alexa Fluor 594 goat anti-
rabbit IgG (A-11012, Life technologies, CA). The sections were counterstained with 
DAPI and then observed by microscopy. 
Construction of the lentiviral GLP-1R-expressing vector and transduction of cells 
We constructed a lentiviral vector including a FLAG epitope tag as described previously 
15, using pFLAG CMV-2 expression vector (Cat. # E7033 Sigma-Aldrich, Saint Louis, 
MO, USA), pLVSIN-EF1α (Cat. #6186, Clontech, Mountain View, CA, USA) and 
293T cells (#CRL-3216; ATCC, Manassas, VA, USA).  
Cell culture and proliferation assay 
Cells were maintained in RPMI 1640 medium with supplementations, 10% fetal bovine 
serum (FBS) and 1% penicillin/streptomycin. The cell proliferation assay was 
performed as described previously10 with minor modifications. Briefly, cells were 
cultured in 12-well culture plates and maintained in medium with or without 0.1–10 nM 
Ex-4 or 100 nM exendin (9–39) (E7269, Sigma-Aldrich), and with or without PKI14-22 
(P9115, Sigma-Aldrich). Cell proliferation ratio was counted after 0–3 days or 48 h 
using a hemocytometer. 
Animals 
Male athymic CAnN.Cg-Foxn1nu/CrlCrlj 5 weeks aged mice were purchased from 
Charles River Laboratories Japan, Inc. (Kanagawa, Japan) and housed in a specific-
pathogen-free barrier facility at Fukuoka University. The mice were subcutaneously 
injected with 5,000 ALVA-41-GLP-1R or ALVA-41-control cells stably expressing the 
Luciferase gene controlled the CAG promoter (catalogue no. LVP567; GenTarget Inc., 
San Diego, CA, USA), which were mixed with 100 L Matrigel (Becton Dickinson, 
Bedford, MA, USA)15, at 6 weeks of age. Mice were treated with either saline or Ex-4 
(Sigma-Aldrich, Tokyo, Japan), as we described previously10. At 10 weeks of age, 
tumor growth was evaluated using an IVIS Lumina In Vivo Imaging System16. After 
imaging, mice were euthanized and their tumors were resected. The tumor volume was 
calculated as we previously described10. The plasma glucose consentration was 
measured by Glutest Neo Super (Sanwa Chemical Co., Kanagawa, Japan). All protocols 
involving animals were reviewed and approved by the Animal Care Subcommittee at 
Fukuoka University. All methods involving animals were performed in accordance with 
the relevant guidelines and regulations. 
Reverse Transcription (RT) and quantitative real-time RT- Polymerase Chain 
Reaction (PCR)  
To analyze gene expression, RT and quantitative real-time PCR were performed as 
described previously10. Each sample was examined in triplicate and corrected by 
internal control, TATA-binding protein (TBP) mRNA expression. The primer sequences 
were same to our previous report10. PCR products were separated by agarose gel 
electrophoresis and visualized by ethidium bromide staining. 
Bromodeoxyuridine (BrdU) incorporation assay 
To evaluate the proliferation of ALVA-control or ALVA-41-GLP-1R cells with or 
without Forskolin (#F6886; SIGMA-ALDRICH, Tokyo, Japan). BrdU assay was 
performed using a Cell Proliferation ELISA kit (1647229; Roche Applied Science, 
Mannheim, Germany), as described previously10, 11.  
Apoptosis assay 
To detect apoptotic cells, TUNEL staining was demonstrated using the DeadEnd 
Fluorometric TUNEL System (Promega), according to the conpany’s protocol, as we 
previously described10.  
Measurement of the cAMP concentration 
Measurement of the cAMP concentration was performed as described previously10, using 
a cAMP Enzyme Immunoassay Kit (#501040; Cayman Chemical, Ann Arbor, MI, USA), 
according to the company’s instructions. 
Cell cycle analysis by flow cytometry 
Cell cycle analysis by flow cytometry was performed as reported previously6. Briefly, 
ALVA-41 cells were seeded in 60-mm dishes at 1×105 cells/ml. Cells were grown to 
60%–70% confluency with 10 nM Ex-4 or PBS for 48 h. Cell cycle analysis was 
performed using a Cycletest™ Plus DNA reagent kit (BD Biosciences Franklin Lakes, 
NJ, USA), following the manufacturer’s instructions, and BD FACSVerse (BD 
Biosciences). Flow cytometry data were analyzed using FlowJo software (Tree Star, 
Inc., OR, USA). 
Western blotting analysis 
Western blotting was performed as described previously6, 10. The following primary 
antibodies were used: phospho-ERK (Thr-202/Tyr-204) (#9101, Cell Signaling, 
Danvers, MA, USA), ERK (#9102, Cell Signaling), cyclin D1 (#2978, Cell Signaling), 
cyclin D2 (#3741, Cell Signaling), phospho-Rb (Ser807/811) (#8516, Cell Signaling), 
p27Kip1 (#3686; Cell Signaling), and GAPDH (sc-20357; Santa Cruz Biotechnology, 
Dallas, TX, USA). 
Statistical analysis 
The unpaired t-test or one-way ANOVA were performed for statistical analysis as 
appropriate. P-values of less than 0.05 were considered as statistically significant. Results 
are expressed as the mean ± SEM. 
 
RESULTS 
GLP-1R expressed in human prostate cancer is inversely associated with cancer 
progression 
As we reported previously10, GLP-1R is observed in prostate cancer tissue in non-diabetic 
subjects and colocalizes with P504S, prostate cancer marker. Interestingly, as shown in 
Figure 1A, Expression levels of GLP-1R were decreased in advanced prostate cancer 
categorized by the Gleason score13. When the 30 patients were divided into three groups 
according to the Gleason score, expression of GLP-1R in prostate cancer was 
significantly decreased in advanced prostate cancer patients with high Gleason scores 
compared with early stage prostate cancer patients (Figure 1B). 
Forced expression of GLP-1R attenuates prostate cancer cell proliferation 
To elucidate the effect of GLP-1R expression on prostate cancer, we overexpressed GLP-
1R in prostate cancer cells. In our previous report10, endogenous GLP-1R expression was 
negligibly detected in ALVA-41 cells. In the present study, we overexpressed human 
GLP-1R in ALVA-41 cells using a lentiviral vector. As shown in Figure 1C, GLP1R gene 
expression was abundantly detected in ALVA-41 cells transfected with the lentiviral 
vector carrying the human GLP1R gene (ALVA-41-GLP-1R cells) compared with 
LNCaP cells that express endogenous GLP-1R. However, GLP-1R expression was not 
detected in cells transfected with the empty lentiviral vector (ALVA-41-control cells). 
Furthermore, immunohistochemistry of GLP-1R confirmed significant membranous 
GLP-1R protein expression in ALVA-41-GLP-1R cells (Figure 1D). The functional 
effectiveness of overexpressed GLP-1R was demonstrated by intracellular cAMP 
induction in ALVA-41-GLP-1R cells stimulated with Ex-4 (Figure 1E). We next 
examined the anti-proliferative effect of GLP-1R in ALVA-41 cells. As shown in Figure 
2A, the number of ALVA-41-GLP-1R cells was slightly but significantly reduced 
compared with ALVA-41-control cells without GLP-1R agonist treatment. In addition, 
Ex-4 decreased the number of ALVA-41-GLP-1R cells dose-dependently, as shown by 
the growth curve in Figure 2B. However, ALVA-41-control cells did not respond to Ex-
4 (Figure 2C). Consistent with the growth curve data, BrdU incorporation assays 
demonstrated that the proliferation of ALVA-41-GLP-1R cells was decreased 
significantly compared with that of ALVA-41-control cells (Figure 2D). In addition, Ex-
4 attenuated ALVA-41-GLP-1R cell proliferation in a dose-dependent manner, but not 
ALVA-41-control cell proliferation (Figure 2E). Similar to our previous report using 
LNCaP cells10, GLP-1R activation did not induce apoptosis of ALVA-41-GLP-1R cells 
(Figure 2F). 
Forced expression of GLP-1R attenuates cell cycle progression via inhibition of 
SKP2 and upregulation of p27Kip 1 
We next examined the mechanism by which overexpressed GLP-1R attenuated ALVA-
41 cell proliferation. First, we conducted cell cycle analysis by flow cytometry. As shown 
in Figure 3A, ALVA-41-GLP-1R cells in G0/G1 phase were increased and those in S 
phase were decreased compared with ALVA-41-control cells. Furthermore, Ex-4 
treatment decreased not only S phase entry, but also G2/M phase transition of ALVA-41-
GLP-1R cells (Figure 3B). Consistent with the apoptosis assay (Figure 2F), the subG1 
fraction was not observed after Ex-4 treatment, further supporting suppression of 
apoptosis. In Figure 3A, significantly increased G0/G1 was observed in ALVA-41-GLP-
1R compared with ALVA-41-control, but not in Figure 3B. This might be an experimental 
limitation, because Figure 3B require 12 hours longer incubation time for PBS or Ex-4.  
Because exendin (9–39), a GLP-1R antagonist (Figure 3C) and inhibitor of protein kinase 
A (PKA; Figure 3D), significantly counteracted Ex-4-induced attenuation of cell 
proliferation, Ex-4 inhibited cell proliferation via the activation of GLP-1R and cAMP-
PKA signaling, a canonical pathway of GLP-1R. In our previous report using LNCaP 
cells, Ex-4 attenuated cell proliferation via inhibition of ERK10. However, ERK was not 
activated in ALVA-41 cells (Figure 3E). To confirm anti-proliferative effect of 
intracellular cAMP induced by GLP-1R signal, we demonstrated BrdU assay with 
Forskolin which is a ubiquitous activator of eukaryotic adenylyl cyclase to increase 
cAMP level. As shown in Figure 3F, Forskolin decreased cell proliferation in ALVA-41 
cell significantly, and further reduction of cell proliferation was observed in ALVA-41-
GLP-1R cell. Because G0/1 arrest was obviously induced by GLP-1R activation in 
ALVA-41 cells, we performed further experiments focusing on cell cycle regulators. 
Western blotting revealed no significant differences in Rb protein phosphorylation and 
cyclin D1 expression between ALVA-41-GLP-1R and ALVA-41-control cells without 
Ex-4 treatment (Figure 4A, B). However, p27Kip 1, a negative regulator of G0/1-to-S 
phase entry, was significantly increased in ALVA-41-GLP-1R cells compared with 
ALVA-41-control cells (Figure 4C). Furthermore, Ex-4 treatment significantly decreased 
Rb phosphorylation (Figure 4D) and cyclin D1 expression (Figure 4E), and significantly 
increased p27Kip1 expression (Figure 4F) in ALVA-41-GLP-1R cells, but not in ALVA-
41-control cells. Because p21Kip1 protein levels are post-translationally regulated by 
SKP2 ubiquitin ligase, we next examined SKP2 expression by quantitative RT-PCR. As 
shown in Figure 4G, SKP2 gene expression was decreased significantly by Ex-4 in 
ALVA-41-GLP-1R cells, but not in ALVA-41-control cells.   
Forced expression of GLP-1R attenuates prostate cancer growth in vivo independent 
of glucose metabolism 
To determine the anti-prostate cancer effect of overexpressed GLP-1R in vivo, we 
implanted ALVA-41-GLP-1R and ALVA-41-control cells, which stably expressed 
cytomegalovirus-luciferase (CAG-Luc), as reported previously16, into athymic nude mice. 
Four weeks after subcutaneously implantation of ALVA-41 cells into the flank region of 
mice, tumor formation was visualized by in vivo imaging of the fluorescence intensity 
derived from CAG-Luc in ALVA-41 cells just prior to sacrifice (Figure 5A). The tumor 
growth measured by the fluorescence intensity of ALVA-41-GLP-1R cells was decreased 
compared with that of ALVA-41-control cells without Ex-4, but it was not statistically 
significant. However, Ex-4 treatment significantly reduced the tumor growth of ALVA-
41-GLP-1R cells compared with that of ALVA-41-control cells without Ex-4 (Figure 5B). 
In resected tumors, the calculated tumor growth of ALVA-41-GLP-1R cells was 
attenuated, but it was not statistically significant (Figure 5C). However, the tumor weight 
of ALVA-41-GLP-1R cells was decreased significantly compared with that of ALVA-
41-control cells without Ex-4, and Ex-4 treatment significantly decreased the tumor 
weight of ALVA-41-GLP-1R cells comparing with that of ALVA-41-control cells treated 
with Ex-4 (Figure 5D). During the experimental period, serum glucose levels and body 
weights were not significantly different between the four groups (Figure 5E, F). 
 
DISCUSSION 
We investigated that expression of GLP-1R in human prostate cancer cells was 
inversely associated with cancer progression, and that forced expression of GLP-1R 
inhibited prostate cancer cell proliferation in vivo and in vitro by attenuating cell cycle 
progression, in the present study. Incretin therapies have recently emerged as major anti-
diabetic agents in the world17 including Japan18. Several advantages of incretin therapy, 
such as a protection of pancreatic -cells, possibility of body weight loss, and fewer 
hypoglycemic events, have been reported19. Furthermore, incretin therapy is one of the 
therapeutic options for T2DM even in chronic renal failure20. In addition, recent large-
scale randomized control trials have suggested that GLP-1R agonists significantly 
reduced cardiovascular events21, 22. Following these evidences, the early use of GLP-1R 
agonists is recommended by the American Diabetes Association, especially for patients 
with established atherosclerotic cardiovascular and chronic kidney diseases23. However, 
the currently emerging consideration for incretin therapies should be their long-term 
guaranteed safety, including the cancer risk. 
The mechanism-of-action of GLP-1 on cancer is still under elucidation, as we 
described in a previous review24. Although some data have indicated a risk of 
carcinogenesis by GLP-1R agonist use, there is no evidence that GLP-1R agonists 
increase cancer onset or death in randomized control trials. Nonetheless, we have 
previously investigated anti-cancer effects of a GLP-1R agonist in not only prostate 
cancer models10, 11, but also in breast cancer15 models. These data suggest anti-cancer 
effects of GLP-1R agonists. Among numerous cancers associated with DM and metabolic 
syndromes25, the association between prostate cancer and DM is controversial, and some 
data suggest that patients with T2DM have a lower risk of prostate cancer compared with 
non-diabetic subjects26. However, a higher incidence of prostate cancer has been observed 
in large-scale studies conducted in Western countries12 and in Japan also9. Further, a 
higher BMI and higher plasma C-peptide concentrations increase prostate cancer 
mortality27. Previously, we have demonstrated that insulin-like growth factor-I (IGF-I) 
and insulin increase prostate cancer cell proliferation in vitro28. These data suggest that 
caution is needed regarding prostate cancer, especially in obese and insulin-resistant 
patients with T2DM. Expression level of GLP-1R was inversely associated with the 
Gleason score and prostate cancer advances (Figure 1A, B), in human prostate cancer. 
These data indicate that the activation of GLP-1R could be a marker of early stage prostate 
cancer, and that GLP-1R agonist may be a therapeutic option for patients with T2DM 
complicated with early stage prostate cancer based on our previous report10 and the 
present study. In our earlier study, Ex-4 attenuated LNCaP cell proliferation by inhibiting 
ERK activation10. However, in ALVA-41 cells, ERK was not activated (Figure 3E). As 
clearly explained in review article29, ERK is one of the most important growth signal in 
prostate cancer. However, ALVA-41 does not have ERK, probably because ALVA-41 is 
a cell line from bony metastasis from human prostate cancer, not primary prostate 
cancer30, and some transformation might happen in growth signal. In addition, cAMP 
response element binding protein (CREB) is one of the most major transcriptional factor 
activated by ERK phosphorylation, and we have previously demonstrated that Ex-4 
decreased CREB phosphorylation in vascular smooth muscle cell6. While CREB was 
slightly detected in ALVA-41 cell, phosphorylation of CREB was not detected and 
modified in ALVA-41 cell with or without GLP-1R expression and Ex-4 treatment 
(Supplementary Figure 1). Further, to confirm anti-prostate cancer effect of GLP-1R, we 
demonstrated forced expression of GLP-1R in PC3 cell, a popular prostate cancer cell 
line. As shown in Supplementary Figure 2, Ex-4 attenuated cell proliferation in PC3 cell 
force-expressed GLP-1R. Interestingly, overexpression of GLP-1R and treatment with 
Ex-4 attenuated ALVA-41 cell proliferation by inhibiting cell cycle progression, which 
was independent of ERK activation, suggesting that GLP-1R activation attenuates cell 
proliferation by activating different signaling pathways depending on the cell types. In 
the present study, GLP-1R activation decreased SKP2 expression and subsequently 
increased p27Kip 1 protein levels to induce G0/1 arrest and inhibit cell cycle progression. 
In fact, we have reported a similar effect of Ex-4 in vascular smooth muscle cells 
(VSMCs)6. Ex-4 inhibited SKP2 expression and attenuated VSMC proliferation and 
neointima formation after vascular injury6. These data suggest that SKP2 might be a 
critical regulator of the anti-proliferative effect of GLP-1R activation in proliferating cells 
such as cancer cells and VSMCs. SKP2 is an F box protein that regulates p27Kip 1 
ubiquitination and degradation, functioning as an ubiquitin ligase31. Interestingly, an 
opposing interaction between the GLP-1 action and SKP2 has been reported by another 
study32. GLP-1 upregulates SKP2 expression and additionally downregulates p27Kip 1 
expression to accelerate cell proliferation through an insulin receptor substrate 2-
dependent signal transduction in pancreatic -cells32. The interaction between GLP-1 
signaling and SKP2 is most likely influenced by cell proliferative activity and other 
growth signals. In the present study, key mechanism by which Ex-4 attenuated ALVA-
41 cell via GLP-1R activation could be upregulation of cAMP level, because Forskolin 
also decreased ALVA-41 cell proliferation. In fact, it is reported that cAMP activates 
SKP2 expression and attenuates cell proliferation in vascular smooth muscle cell33. SKP2 
induction by cAMP increased by GLP-1R signal could be one of mechanism by which 
GLP-1 attenuates prostate cancer growth, similar to ERK inhibition10. In addition, an 
association between GLP-1R and prostate cancer has not been investigated by genome-
wide research. Although relationships between variants of TCF7L2 (transcription factor 
7-like 2), one the most important transcription factors for GLP-1R expression, and some 
cancers, such as breast, colorectal and lung cancers, have been reported34, further 
elucidation is required. 
Considering primary action of GLP-1, GLP-1R agonists are anti-diabetic agent 
which induce anti-apoptotic action and cell proliferation of pancreatic cells via ERK, 
Akt and -catenin activation35. However, the present data and our previous reports10, 11, 15 
suggested anti-proliferative effect of GLP-1R agonist in cancer cells. These two actions 
seem opposite effect. Among cancer cells, Koehler et al. reported that GLP-1R agonist 
Ex-4 does not modify cell growth and apoptosis in pancreatic cancer cells36. GLP-1 action 
and downstream signal of GLP-1R might be different depending on cell line and 
cancerous or not cancerous cell. Further elucidation about GLP-1R signal depending on 
cell background and cross talking with other signal transductions should be required.    
In conclusion, we investigated an anti-prostate cancer effect by overexpressed GLP-1R 
activation in vitro and in vivo. The present study may facilitate establishing diabetes 
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FIGURE LEGENDS 
Figure 1. GLP-1R expression in human prostate cancer and overexpression of 
human GLP-1R in ALVA-41 cells.  
A. Immunohistochemistry of GLP-1R and P504S was performed to examine GLP-1R 
expression in human prostate cancer tissues obtained by prostate gland resection or biopsy. 
Staining is representative of prostate cancer tissues from 10 independent non-diabetic 
patients. Sections were stained with anti-GLP-1R or P504S antibodies and counterstained 
with DAPI (magnification, ×400). B. GLP-1R-positive cells and cancerous P504S-
positive cells were counted in four individual fields of view. One-way ANOVA was 
performed to calculate statistical significance (**P<0.01 vs. Gleason 6, #P<0.05 vs. 
Gleason 7). C. RT-PCR of the coding sequence of human GLP1R was performed to detect 
GLP1R expression. TBP was used as the internal control. D. Immunohistochemistry was 
performed to detect expression of human GLP-1R in ALVA-41 and LNCaP cells. E. The 
intracellular cAMP concentration was measured in ALVA-41-control and ALVA-41-
GLP-1R cells with or without Ex-4 stimulation. The unpaired t-test was performed to 
calculate statistical significance (**P<0.01 vs. 0 min) (n=3). 
Figure 2. Attenuation of prostate cancer cell proliferation by overexpression of 
GLP-1R and Ex-4 stimulation. 
Growth curves of ALVA-41-control and ALVA41-GLP-1R cells without Ex-4 A, 
ALVA-41-GLP-1R cells with or without Ex-4 B, and ALVA-41-control cells with or 
without Ex-4 C. A. The unpaired t-test was performed to calculate statistical significance 
(*P<0.05, **P<0.01 vs. ALVA-control) (n=3). B, C. One-way ANOVA was performed 
to calculate statistical significance (*P<0.05, **P<0.01 vs. PBS) (n=3). D, E. BrdU 
assays were performed to measure DNA synthesis in ALVA-41-control and ALVA-41-
GLP-1R cells with or without Ex-4 for 24 h. Data are expressed as relative absorbance to 
ALVA-41-control D and 0 nM Ex-4 in ALVA41-control or ALVA-41-GLP-1R cells. The 
unpaired t-test was performed to calculate statistical significance. D. *P<0.05 vs. ALVA-
41-control (n=3). E. *P<0.05, **P<0.01 vs. 0 nM Ex-4 (n=3).  
Figure 3. Cell cycle distribution and signal transduction.  
A, B Flow cytometric analysis was performed to determine the cell cycle distribution of 
ALVA-41-control and ALVA-41-GLP-1R cells with or without Ex-4. Data are 
represented as the ratios of cells distributed in each phase to the total cells. The unpaired 
t-test was performed to calculate statistical significance. A. *P<0.05 vs. ALVA-41-
control (n=3). B *P<0.05 vs. ALVA-41-control and #P<0.05, ##P<0.01 vs. ALVA-41-
GLP-1R+PBS (n=3). C, D. Growth curves of ALVA-41-GLP-1R cells with or without 
Ex-4, Ex9–39, or PKI. The unpaired t-test was performed to calculate statistical 
significance for C *P<0.05 vs. PBS and #P<0.05 vs. Ex-4+Ex9–39 (n=3), and D *P<0.05 
vs. PBS and #P<0.05 vs. Ex-4+PKI (n=3). E. Western blotting of phospho-ERK, ERK, 
and GAPDH was performed in three independent ALVA-41 cell lysate samples. F. BrdU 
assay were performed to measure DNA synthesis in ALVA-41-control and ALVA-41-
GLP-1R with or without Forskolin (FK) for 24 h. Data are expressed as relative 
absorbance compared with 0μM Forskolin in ALVA41-control or ALVA-41-GLP-1R. 
One-way ANOVA with a post hoc Dunnett’s test was performed to calculate statistical 
significance. *P<0.05, **P<0.01 vs. EtOH (0μM) (n=5).   
 
Figure 4. Expression of cell cycle regulators in ALVA-41-GLP-1R cells. 
Western blotting of A, D phosphorylated Rb, B, E cyclin D1, and C, F p27Kip 1 was 
performed in ALVA-41-control and ALVA-41-GLP-1R cells with or without 10 nM Ex-
4 for 24 h. Densitometry was performed by normalization to GAPDH. Data are 
represented as relative expression to ALVA-41-control cells A–C or cells treated with 
PBS D–G. Quantitative real-time RT-PCR of SKP2 was performed in ALVA-41-control 
and ALVA-41-GLP-1R cells with or without 10 nM Ex-4 for 24 h. The unpaired t-test 
was performed to calculate statistical significance. C. *P<0.05 vs. ALVA-41-control D–
G. *P<0.05 vs. ALVA-41-GLP-1R treated with PBS.  
Figure 5. Forced expression of GLP-1R attenuates prostate cancer growth in vivo.  
A. ALVA-41-control or ALVA-41-GLP-1R cells stably transfected with the Luciferase 
gene were implanted into athymic nude mice with or without Ex-4 treatment. Tumor 
growth was visualized using an in vivo imaging system. B. Quantification of 
fluorescence were determined in tumor cells. C. Tumor volumes were calculated by the 
modified ellipsoid formula. D. Tumor weight was measured by balance. E. Plasma 
glucose and F. body weight were measured during the experimental period. The 
unpaired t-test was performed to calculate statistical significance: *P < 0.05 vs. ALVA-
41-control+PBS, #P<0.05 vs. ALVA-41-control+Ex-4. 
              
 
    
 
  
 
 
 
 
 






